The title must be entered exactly as it should appear and should be in sentence case. Do not put the title in quotes, underline it, or use punctuation. The title can be a maximum of 200 characters, including spaces.
Example: Novel pharmacologic approach to enhance the epigenetic and immune priming effect of decitabine in patients with advanced non-small cell lung cancer
Abstract submitters that select the presentation type “Oral or Poster” will be asked to indicate the session they feel the abstract would most belong in. Abstracts will be reviewed and chosen by the Co-Chairs of the session selected.
All abstract submitters will be asked to indicate the category that they feel the abstract most belongs to. If accepted, this selection will determine the category your abstract is listed under in publications such as the Annual Meeting Abstract Book and the JITC supplement as well as the category used for poster displays.
All abstract submitters will be asked to indicate keywords for their abstract. Keywords are included in the Annual Meeting Abstract Book, website and app publications to assist users in searching for abstracts. Up to 10 keywords can be selected.
The following is included in the abstract body and must not exceed 400 words total.
*For Clinical Trials In Progress, if results and conclusion are not applicable please put N/A when submitting
The following are no longer required to stay within the 400 word limit.Acknowledgements:
Brief acknowledgements may be included.Trial Registration:
If applicable, abstracts related to randomized controlled clinical trials (RCTs) should include the trial registry along with the unique identifying number. Trial registers that currently meet the publisher’s requirements can be found at http://www.icmje.org/about-icmje/faqs/clinical-trials-registration/
Citations to references should be included in square brackets [1,2]. All references need corresponding citations in the text, and vice versa.
Journal abbreviations should follow MEDLINE standards. References should be laid out at the end of the abstract.
Lastname A, Lastname B, Lastname C. Title of journal article. Journal Medline abbreviation. Year; Volume:first page-last page.
Chomczynski P, Sacchi N, Single-step method of RNA isoloation by acid guanidinium thiocyanate-phernol-chloroform extraction. Anal Biochem. 1987;162:156-159.
Web links (URLs) should be provided in full, including both the title of the site and the URL, in the following format:
Mouse Tumor Biology Database
If the abstract discusses studies involving human subjects, human material, or human data, or involving animals, an ethics statement should be included: "The study was approved by XYZ instution's Ethics Board, approval number 12345."
If applicable, for abstracts containing sensitive or identifiable information, written consent to publish must be obtained from the study participant(s) by authors. In these cases authors should include a ‘consent’ section in their abstract and we recommend using the following wording: “Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.”
Authors and Institutions
All authors and contact information must be listed in the correct order. The order in which authors will be listed in the author block of all publications including online, the Annual Meeting Abstract Book, and the JITC Supplement is the order that they are entered.
Each author MUST indicate at least one institution affiliation. Affiliations should include Department, University, Town, State, USA OR Institution, Town, Country, for example:
1Pathology Department, New York School of Medicine, New York, NY, USA
2Roche Innovation Center Penzberg, Penzberg, Germany
Your submission needs to have a minimum of:
- 1 Corresponding Author
- 1 Presenting Author
- 1 Primary Author
The presenting author will need to complete a Conflicts of Interest Disclosure Form. Once the abstract is submitted, the presenting author will be sent an email notification to complete the form.
The corresponding author will be highlighted and their email provided in the JITC supplement.
There is no limit to the number of authors you can include.
The author submitting an abstract to the SITC 33rd
Annual Meeting must agree to the following:
Tables, Figures and Images
- Serve as the contact for all correspondence about the abstract and inform co-authors about its status.
- Confirm all authors are aware of and agree to the content and data presented in the abstract.
- Verify the abstract is accurate and that permission has been obtained from all relevant parties.
- Verify the abstract has not been published prior to the SITC 33rd Annual Meeting, or if previously published, contains significant new data.
- Agree that the full abstract content submitted to the SITC 33rd Annual Meeting is embargoed until 8 a.m. EST on Nov. 6, 2018.
- Agree to release of the abstract title prior to the SITC embargo date and time of 8 a.m. EST on Nov. 6, 2018. Regular abstract titles will be released on October 1, 2018 and late-breaking abstract titles will be release on November 1, 2018.
- Agree to follow all media and press release policies set forth by SITC.
- Tables, figures and images should be numbered (ie: Table 1, Figure 1, or Image 1) in the title field with an optional caption.
- The title and caption are not include in the total abstract word count.
- All figures, tables, and images need corresponding citations in the text. Citations to any figures (Figure 1), tables (Table 1) or images (Image 1) must also be included in round brackets. All figures and tables need corresponding citations in the text, and vice versa.
- There is not a limit to the number of figures that can be included.
- Figures must be supplied electronically at 300 dpi minimum (600 dpi preferred).
- Do not include figures with embedded hyperlinks.
- The following file types will be accepted: .png, .jpg, .gif
Late-Breaking Abstracts: Late-breaking abstract applications will need to indicate if it is a clinical or lab-based study and will need to include the following information in their application:
- Closure date of the study
- Primary clinical endpoint for analysis
- Type of analysis
- Provide an explanation why the experiment(s) could not be completed before the regular abstract submission deadline, Aug. 1, 2018, and needs to be considered for late-breaking submission.
Young Investigator Awards Abstracts: Abstracts that qualify for a Young Investigator Award and indicate they would like to be considered as a Young Investigator Award abstract will need to include the following information in their application:
- Upload a letter of recommendation from a supervisor (.doc, .docx, .pdf).
- Confirm if they are a SITC member.
- Confirm if they are a student, postdoctoral research fellow, clinical fellow, or junior faculty with three or fewer years on staff, and if so, which they are.
- Indicate the percentage of contribution by the primary and presenting author in regards to conception and design, collection and assembly, data analysis and interpretation, and abstract writing.
Late-Breaking Abstract Information and Eligibility
Late-breaking abstract submission is solely for abstracts with late-breaking data and not for abstracts submitted “late.” The late-breaking abstract deadline is not intended to be an extension of the general submission deadline. Late-breaking abstracts highlight novel and practice-changing studies, and only apply to data that would have not otherwise have been presented as an abstract at the 33rd Annual Meeting.
Examples of acceptable late-breaking abstracts include the following (in each case, results were not available or significant by the regular abstract submission deadline):
- Results of a practice-changing prospective Phase III clinical trial
- Phase II study showing anti-tumor activity in a novel context
- An early clinical trial with novel proof-of-principle data
- Demonstration of novel cancer biology with therapeutic implications
For clinical studies, authors need to justify late consideration by documenting the closure date of the study, and submit a late-breaking abstract application by the regular abstract submission deadline (Aug. 1). This application needs to include necessary abstract information (without results and conclusions) and incorporate the primary clinical endpoint for analysis, type of analysis, date of planned analysis, and planned statistical methods for analysis.
Laboratory-based studies need to be justified within the author's late-breaking abstract application. Authors need to specify why experiments could not be completed before the standard abstract deadline.
The data in the abstract must not be published prior to the SITC 33rd Annual Meeting.
Late-breaking abstracts are considered for, but not limited to, oral abstract presentations during the Late-Breaking Abstract Sessions from Noon – 12:30 p.m. on Friday, Nov. 9 and 11:35 a.m. – 12:05 p.m. on Saturday, Nov. 10.